Australia Oxygen Concentrator Market Projected to Reach USD 189.21 Million by 2033

Market Overview
The Australia oxygen concentrator market was valued at USD 98.00 Million in 2024 and is projected to reach USD 189.21 Million by 2033. The market is growing steadily with a compound annual growth rate of 6.80% during 2025-2033. Growth is driven by rising respiratory diseases, technological advances, and increased awareness about oxygen therapy at home. Government initiatives and a growing geriatric population opting for reliable oxygen therapy solutions are also key factors. For more detailed insights, visit the Australia Oxygen Concentrator Market report.

https://www.imarcgroup.com/australia-oxygen-concentrator-market

How AI is Reshaping the Future of Australia Oxygen Concentrator Market:
• AI-enabled portable oxygen concentrators are becoming more prevalent, providing efficient oxygen delivery with smart monitoring and remote control capabilities.
• Integration of AI sensors helps in real-time health data tracking for chronic respiratory patients, enabling personalized therapy adjustments.
• AI algorithms optimize battery life and energy consumption in devices, responding to user activity and environmental changes, improving usability.
• Government funding supports research into AI-based oxygen therapy solutions tailored for remote and indigenous communities, enhancing accessibility.
• Companies are leveraging AI-driven predictive maintenance to reduce device downtime, ensuring consistent oxygen supply for home care patients.
• AI-powered telehealth platforms connected to oxygen concentrators facilitate remote monitoring by healthcare providers, improving patient outcomes.

Grab a sample PDF of this report:
https://www.imarcgroup.com/australia-oxygen-concentrator-market/requestsample

Market Growth Factors
The rising prevalence of chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma significantly fuels the demand for oxygen concentrators in Australia. According to the AIHW's 2024 Burden of Disease Study, asthma's burden has increased by 8.5% since 2003, ranking eighth highest overall. In children aged 5-14, it accounted for 11.9% of the total disease burden, impacting males (12.8%) and females (10.7%) alike. These respiratory conditions necessitate long-term oxygen therapy to control symptoms, reduce hospitalizations, and improve patient health. Increased awareness regarding home oxygen therapy benefits is direct evidence of this driver.

Australia's rapidly aging population also propels market growth. The Centre for Population data shows that nearly 25% of the population will be aged 65 and over by 2064-65. Chronic illnesses common in elderly populations, including COPD and emphysema, require long-term oxygen support. This demographic shift increases the adoption of both portable and stationary oxygen concentrators, preferred for home-based therapy due to convenience and comfort. Government healthcare reforms and improved affordability of oxygen concentrators further contribute to sustained growth by addressing both native and Indigenous healthcare needs.

Environmental factors represent a critical growth driver in Australia's oxygen concentrator market. Frequent bushfires, dust storms, and pollen season peaks in regions like New South Wales, Victoria, and Western Australia deteriorate air quality, exacerbating respiratory issues. These hazards increase hospital admissions and highlight the need for at-home respiratory therapy solutions. Given Australia's vast and isolated communities, portable concentrators provide timely, stable oxygen delivery where hospital access is limited. This regional vulnerability to environmental risks stimulates demand for oxygen concentrators capable of reliable performance in diverse and challenging climates.

Market Segmentation
Type:
• Portable
• Stationary

Technology:
• Continuous Flow
• Pulse Flow

Application:
• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Respiratory Distress
• Others

End User:
• Hospitals and Clinics
• Home Care Settings
• Ambulatory Surgical Centers and Physician Offices

Regions:
• Australia Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Recent Development & News
• June 2025: The Australian government collaborated with healthcare and technology sectors to launch educational programs promoting the benefits of home oxygen therapy, resulting in an increase in patient adoption by 15% within targeted communities.
• August 2025: A leading oxygen concentrator manufacturer expanded its distribution network across regional Australia, introducing a new portable product line with enhanced battery life and AI-based monitoring features, diversifying consumer options.
• October 2025: Market data revealed a 12% increase in home care oxygen therapy uptake, driven by improved reimbursement policies and subsidies, indicating robust market penetration in rural and remote areas.

Customization Note:
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
https://www.imarcgroup.com/request?type=report&id=33704&flag=F

Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302

About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.